#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	3306	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2444	401.2	0	.	n	.	0	C1450T	SNP	1450	1450	C	1878	1878	T	472	T,G	411,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	3306	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2444	401.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1612	1612	C	505	C	419	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5176	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4155	373.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1975	1975	A	433	A,G,C	350,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5176	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4155	373.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2609	2609	C	506	C	411	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5176	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4155	373.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2683	2683	A	493	A,C	411,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5176	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4155	373.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	3235	3235	C	425	C	361	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_G_01367c	folP.WHO_G_01367c	1	1	539	436	folP	852	852	99.88	folP.l15.c4.ctg.1	1859	69.6	0	.	p	.	0	E151K	NONSYN	451	453	GAA	939	941	AAA	118;117;117	A;A,C;A	93;91,2;85	.	.
folP.WHO_G_01367c	folP.WHO_G_01367c	1	1	539	436	folP	852	852	99.88	folP.l15.c4.ctg.1	1859	69.6	1	SNP	p	R228S	1	.	.	682	684	AGC	1170	1172	AGC	106;104;104	A,G;G;C	83,1;84;84	folP.WHO_G_01367c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	886	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	3481	76.1	1	SNP	p	S91F	0	.	.	271	273	TCC	575	577	TCC	75;76;76	T;C;C	58;60;60	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	886	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	3481	76.1	1	SNP	p	D95G	0	.	.	283	285	GAC	587	589	GAC	70;71;72	G;A;C	55;54;55	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	886	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	3481	76.1	1	SNP	p	D95N	0	.	.	283	285	GAC	587	589	GAC	70;71;72	G;A;C	55;54;55	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	424	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1677	75.5	1	SNP	p	G45D	0	.	.	133	135	GGC	698	700	GGC	111;111;111	G;G;C,A,T	86;90;86,1,1	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	246	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1290	56.8	0	.	n	.	0	A197.	DEL	197	197	A	669	669	A	110	A	95	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	872	parC	2304	2304	99.91	parC.l6.c4.ctg.1	3361	77.6	1	SNP	p	D86N	0	.	.	256	258	GAC	717	719	GAC	95;95;95	G;A,T;C	73;71,1;74	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	872	parC	2304	2304	99.91	parC.l6.c4.ctg.1	3361	77.6	1	SNP	p	S87W	0	.	.	259	261	AGT	720	722	AGT	95;95;95	A;G;T	69;75;74	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	872	parC	2304	2304	99.91	parC.l6.c4.ctg.1	3361	77.6	1	SNP	p	S87I	0	.	.	259	261	AGT	720	722	AGT	95;95;95	A;G;T	69;75;74	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	872	parC	2304	2304	99.91	parC.l6.c4.ctg.1	3361	77.6	1	SNP	p	S87R	0	.	.	259	261	AGT	720	722	AGT	95;95;95	A;G;T	69;75;74	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	872	parC	2304	2304	99.91	parC.l6.c4.ctg.1	3361	77.6	1	SNP	p	S88P	0	.	.	262	264	TCC	723	725	TCC	95;95;95	T;C;C	77;74;75	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	768	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3110	74.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1705	1707	GGC	109;109;109	G;G;C	91;91;90	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	768	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2713	84.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1359	1361	GCA	112;113;113	G;C;A	90;87;90	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	768	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2713	84.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1362	1364	ATC	114;115;116	A;T,C;C,T	89;88,1;90,1	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	768	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2713	84.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1374	1376	GTG	113;111;110	G;T;G	90;86;88	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	768	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2713	84.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1374	1376	GTG	113;111;110	G;T;G	90;86;88	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	768	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2713	84.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1878	1880	ACC	98;98;99	A;C;C	77;78;77	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	768	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2713	84.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1932	1934	GCG	85;85;87	G;C,G;G,T,C	63;58,1;60,1,1	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	768	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2713	84.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1932	1934	GCG	85;85;87	G;C,G;G,T,C	63;58,1;60,1,1	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	768	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2713	84.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2055	2057	GGC	90;90;90	G;G;C	73;72;74	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	768	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2713	84.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2064	2066	GGC	87;87;87	G;G;C	70;71;69	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	768	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2713	84.8	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2082	2084	CTG	92;91;91	C;T;G	72;72;71	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1154	ponA	2397	2397	100.0	ponA.l6.c4.ctg.1	3468	99.7	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1820	1822	CCG	89;89;89	C;C;G,C	68;73;70,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	526	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2153	73.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	747	747	C	83	C	77	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	80	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	1087	16.0	0	.	p	.	0	H217N	NONSYN	649	651	CAT	824	826	AAT	13;13;13	A;A;T	10;10;10	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	80	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	1087	16.0	0	.	p	.	0	D218N	NONSYN	652	654	GAT	827	829	AAT	13;13;13	A;A;T	10;10;10	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	80	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	1087	16.0	0	.	p	.	0	V226A	NONSYN	676	678	GTA	851	853	GCA	13;13;13	G;C;A	10;10;10	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	80	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	1087	16.0	0	.	p	.	0	.	MULTIPLE	700	702	ACT	874	876	GTA	12;12;12	G;T;A	10;10;10	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	80	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	1087	16.0	0	.	p	.	0	S236N	NONSYN	706	708	AGC	880	882	AAC	12;12;12	A;A;C	9;10;9	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	80	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	1087	16.0	0	.	p	.	0	.	MULTIPLE	709	711	AAC	884	888	TGGCG	12;12;12;12;12	T;G;G;C;G	9;9;9;10;10	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	80	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	1087	16.0	0	.	p	.	0	D238A	NONSYN	712	714	GAT	890	892	GCT	12;12;12	G;C;T	9;10;8	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	80	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	1087	16.0	0	.	p	.	0	V258L	NONSYN	772	774	GTA	950	952	TTA	11;11;12	T;T;A	10;10;10	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	80	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	1087	16.0	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	995	997	CAT	13;13;13	C;A;T	10;10;10	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	80	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	1087	16.0	0	.	p	.	0	D274S	NONSYN	820	822	GAT	998	1000	AGT	13;13;13	A;G;T	10;10;10	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	80	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	1087	16.0	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	1007	1009	TAC	13;13;13	T;A;C	10;10;10	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	636	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1954	96.9	0	.	p	.	0	N38E	NONSYN	112	114	AAT	574	576	GAA	120;121;122	G;A,C;A	99;94,1;98	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	636	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1954	96.9	0	.	p	.	0	N134D	NONSYN	400	402	AAT	862	864	GAT	117;116;116	G;A;T	95;94;97	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	636	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1954	96.9	0	.	p	.	0	P175S	NONSYN	523	525	CCA	985	987	TCA	115;114;115	T;C;A	90;88;92	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	636	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1954	96.9	0	.	p	.	0	D212G	NONSYN	634	636	GAT	1096	1098	GGT	120;119;119	G;G;T	99;94;98	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	636	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1954	96.9	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1114	1116	GTC	121;121;121	G;T;C,A	99;98;99,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	636	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1954	96.9	1	SNP	p	G120K	1	.	.	358	360	AAG	820	822	AAG	122;121;121	A;A;G	105;102;104	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	636	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1954	96.9	1	SNP	p	D121N	0	.	.	361	363	GAC	823	825	GAC	120;120;118	G;A,T;C	99;100,1;99	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	636	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1954	96.9	1	SNP	p	A121D	1	.	.	361	363	GAC	823	825	GAC	120;120;118	G;A,T;C	99;100,1;99	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	2186	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5288	123.8	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2230	2232	AAT	115;115;114	A;A,C;T	95;97,1;96	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	358	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1331	80.1	1	SNP	p	V57M	1	.	.	169	171	ATG	664	666	ATG	150;149;151	A;T;G	117;116;121	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
